Cardiometabolic Benefits Beyond Blood Sugar Control Although glucose control remains important, the broader benefits of GLP-1 therapies cannot be ignored
Personalized Nutrition and Genetic Insights on PlexusDx The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month) analyzes GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) variants that relate to GLP-1 and related signaling pathways
Patients who taper off successfully often retain their results with ongoing guidance and support
It estimates the population level treatment effect of semaglutide regardless of treatment adherence and/or other anti-obesity therapies and does not exclude data collected after discontinuation of treatment (e.g., due to tolerability issues) or after initiation of alternative treatment (e.g., due to lack of efficacy)
Clinicians should consider several potential concerns during evaluation: Unknown active ingredient source Variable potency or concentration Differences in excipients Sterility concerns for injectable products Dosing inaccuracies Limited stability data Inconsistent patient instructions The FDA has also warned healthcare professionals about compounded products made with salt forms of semaglutide that differ from the approved active ingredient
Furthermore, the deletion of Bmal1 in the brain induced apoE expression (inhibiting, e.g., astrocytic clearance of A [73]), potentially elucidating how circadian disruption may increase A burden in the brain
